Tenascin-x facilitates myocardial fibrosis and cardiac remodeling through transforming growth factor-β1 and peroxisome proliferatoractivated receptor γ in alcoholic cardiomyopathy

Chinese Medical Journal

Volumn 124, Issue 3, 2011, Pages 390-395

  Jing, Ling ^a   Zhou, Li Jun ^a   Zhang, Feng Min ^b   Li, Wei Min ^a   Sang, Ying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Alcoholic cardiomyopathy; Cardiac remodeling; Myocardial fibrosis; Tenascin x; TGF 1 PPAR

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMAD3 PROTEIN; SMAD7 PROTEIN; TENASCIN; TENASCIN X; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALCOHOLIC CARDIOMYOPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC REMODELING; CARDIOVASCULAR PARAMETERS; COLLAGEN COLUMN FRACTION; CONTROLLED STUDY; DISEASE ASSOCIATION; FRACTIONAL SHORTENING; HEART CONTRACTION; HEART EJECTION FRACTION; HEART MUSCLE FIBROSIS; LEFT VENTRICLE END DIASTOLE INTERNAL DIAMETER; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, ALCOHOLIC; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, ELECTRON; MYOCARDIUM; PPAR GAMMA; RATS; SMAD3 PROTEIN; SMAD7 PROTEIN; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79551710202     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.03.013     Document Type: Article

References (27)

1. Skotzko CE, Vrinceanu A, Krueger L, Freudenberger R. Alcohol use and congestive heart failure: incidence, importance, and approaches to improved history taking. Heart Fail Rev 2007; 22: 61-67.
2. Klatsky AL. Alcohol and cardiovascular health. Physiol Behav 2010; 100: 76-81.
3. Sakata Y, Chancey AL, Divakaran VG, Sekiguchi K, Sivasubramanian N, Mann DL. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol 2008; 103: 60-68.
4. Wang WM, Liu F, Chen N. Effects of peroxisome proliferators-activated receptor gamma agonists on transforming growth factor-beta1 and Smads signal pathway: experiment with rat renal fibroblasts. Natl Med J China (Chin) 2006; 86: 740-744.
5. Fujie S, Maita H, Ariga H, Matsumoto K. Tenascin-X induces cell detachment through p38 mitogen-activated protein kinase activation. Biol Pharm Bull 2009; 32: 1795-1799.
6. Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, Yoshida T. The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation 2003; 71: 291-298.
7. Chiquet-Ehrismann R, Tucker RP. Connective tissues: signalling by tenascins. Tenascins. Int J Biochem Cell Biol 2004; 36: 986-990.
8. Peeters AC, Kucharekova M, Timmermans J, van den Berkmortel FW, Boers GH, Nováková IR, et al. A clinical and cardiovascular survey of Ehlers-Danlos syndrome patients with complete deficiency of tenascin-X. Neth J Med 2004; 62: 160-162.
9. Chiquet-Ehrismann R. Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200: 488-499.
10. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 2004; 64: 24-31.
11. Zweers MC, Dean WB, van Kuppevelt TH, Bristow J, Schalkwijk J. Elastic fiber abnormalities in hypermobility type Ehlers-Danlos syndrome patients with tenascin-X mutations. Clin Genet 2005; 67: 330-334.
12. Mao JR, Taylor G, Dean WB, Wagner DR, Afzal V, Lotz JC, et al. Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat Genet 2002; 30: 421-425.
13. Wang YN, Liu RL, Cheng XZ. Study of alcoholic poisoning model in rats. Chin J Rehabil Theory Practice 2006; 12: 319-320.
14. Minamitani T, Ikuta T, Saito Y, Takebe G, Sato M, Sawa H, et al. Modulation of collagen fibrillogenesis by tenascin-X and type VI collagen. Exp Cell Res 2004; 298: 305-315.
15. Akiko T, Shozo K, Kunio N, Asami Y, Yutaka K, Satoshi H, et al. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart 1996; 75: 291-294.
16. Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 2006; 27: 715-723.
17. Zhang GY, Cheng T, Zheng MH, Yi CG, Pan H, Li ZJ, et al. Activation of peroxisome proliferator-activated receptorgamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. Arch Dermatol Res 2009; 301: 515-522.
18. Wang B, Omar A, Angelovska T, Drobic V, Rattan SG, Jones SC, et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol 2007; 293: 1282-1290.
19. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, et al. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res 2008; 102: 185-192.
20. Euler-Taimor G, Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res 2006; 69: 15-25.
21. Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, et al. Essential role of smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007; 116: 2127-2138.
22. Dixon IM, Hao J, Reid NL, Roth JC. Effect of chronic AT1 receptor blockade on cardiac smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res 2000; 46: 286-297.
23. Zhao CY, Zhou JY, Yang L, Wang YD. Molecular mechanism of ciglitazone inhibiting the expression of extracellular matrix in human hepatic stellate cells. Chin J Hepatol (Chin) 2007; 15: 840-844.
24. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006; 350: 385-391.
25. Ravingerová T, Adameová A, Kelly T, Antonopoulou E, Pancza D, Ondrejcáková M, et al. Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins. Can J Physiol Pharmacol 2009; 12: 1028-1036.
26. Minamitani T, Ariga H, Matsumoto K. Deficiency of tenascin-X causes a decrease in the level of expression of type VI collagen. Exp Cell Res 2004; 297: 49-60.
27. Matsumoto K, Sato T, Oka S, Inokuchi J, Ariga H. Comparison of the compositions of phospholipid-associated fatty acids in wild-type and extracellular matrix tenascin-x-deficient mice. Biol Pharm Bull 2004; 27: 1447-1450.